Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

GlobeNewswire November 2, 2021

aTyr Pharma to Participate in Piper Sandler Investor Lung Day

GlobeNewswire October 11, 2021

aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs

GlobeNewswire October 6, 2021

aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire October 1, 2021

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 20, 2021

aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

GlobeNewswire September 16, 2021

aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

GlobeNewswire September 16, 2021

aTyr Pharma Announces Proposed Public Offering of Common Stock

GlobeNewswire September 15, 2021

aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

GlobeNewswire September 13, 2021

aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

GlobeNewswire August 10, 2021

aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University

GlobeNewswire August 10, 2021

aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

GlobeNewswire August 9, 2021

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

GlobeNewswire August 3, 2021

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

GlobeNewswire July 29, 2021

aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

GlobeNewswire July 8, 2021

Pharmsynthez PJSC Secures RUB 800m With LDA Capital

Business Wire June 24, 2021

aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

GlobeNewswire June 23, 2021

Love Hemp Group PLC Announces Endorsement Agreement Secured with Anthony Joshua

Accesswire June 21, 2021

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

GlobeNewswire June 10, 2021

Love Hemp Group PLC Announces Issue of Warrants and Issue of Equity

Accesswire June 9, 2021